



Galaxy Surfactants Ltd.

April 02, 2018

National Stock Exchange of India Ltd., Listing Compliance Department Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Scrip Symbol: GALAXYSURF	BSE Limited, Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001 Scrip Code: 540935
--	--

Sub: US FDA Inspection at Tarapur plants M3 & N46

Dear Sir/ Madam,

We wish to inform you that we have five manufacturing facilities in India, one located at Taloja (Maharashtra), three located at Tarapur (Maharashtra) and one located at Jhagadia (Gujarat). Of the facilities at Tarapur, 2 (two) of the facilities viz. M3 s& N46, have undergone US FDA inspection which was concluded on March 30, 2018. These facilities manufacture 2 (two) products viz. Octyl Methoxy Cinnamate and Octocrylene which have USP Monograph.

This is the first USFDA Inspection of our facility and we have been issued Form-483 in which they give their observations. Our M3 plant received 4 (four) and N46 plant received 9 (Nine) observations. All the observations are procedural in nature and none of them were related to any data integrity.

We are in the midst of providing a comprehensive response to the observations and would be replying to the USFDA within the stipulated time. The revenue from the US Market for these 2 products is less than 1% (one percent) of our consolidated revenues and we do not expect any financial impact.

Please take the information on record.

Thanking you,

Yours faithfully,
For Galaxy Surfactants Limited

Niranjn Ketkar
Company Secretary



Regd. Office:

C-49/2, TTC Industrial Area, Pawne,
Navi Mumbai – 400 703, India.

CIN No. U39877MH1986PLC039877

Ph : +91-22-65134444 / 27616666

Fax : +91-22-27615883 / 27615886

E-mail : galaxy@galaxysurfactants.com

Website : www.galaxysurfactants.com